ASRT Earnings

ASRT reported its FY2025Q3 earnings on 2025-11-10, showcasing a revenue of 49.46M against an estimate of 27.02M, resulting in a 83.05% surprise. The EPS was 0.18, surpassing the expected -0.08 by 325%. The stock experienced a 14.89% price change on the earnings day and a -1.25% change over the next five days, reflecting market reactions to the results.

Following ASRT's FY2025Q3 earnings announcement on 2025-11-10, the stock price moved by 14.89% on the day of the release. Over the subsequent five days, it saw a -1.25% change. Historically, ASRT's stock price tends to shift by an average of 0.46% in the 10 days leading up to earnings and -7.19% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate ASRT's annual revenue to reach 14.70M, while the EPS is projected at -0.07. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ASRT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ASRT's stock price typically moves by 0.46% in the 10 days before its earnings and -7.19% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.07 and revenue of 14.70M.

The earnings call presents mixed signals. While Rolvedon sales are expected to stabilize and Sympazan sales have grown, there are concerns with a significant decline in cash reserves and negative adjusted EBITDA. The Q&A reveals confidence in growth and potential for Rolvedon, but also highlights competition for Indocin and vague responses on asset divestment. The positive gross margin and reduced SG&A expenses are offset by a widened net income loss. Overall, these factors suggest a neutral market reaction.